NovoCure (NASDAQ:NVCR) Price Target Raised to $49.00

NovoCure (NASDAQ:NVCR) had its price target increased by HC Wainwright from $47.00 to $49.00 in a research note released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

A number of other research firms have also recently issued reports on NVCR. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research note on Thursday, January 22nd. Evercore set a $20.00 price objective on NovoCure in a research report on Monday, January 5th. Finally, Wedbush reissued a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research note on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, NovoCure has an average rating of “Hold” and a consensus target price of $26.93.

NovoCure Stock Down 0.6%

NovoCure stock opened at $13.67 on Thursday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -11.20 and a beta of 0.73. The company’s 50 day simple moving average is $12.73 and its 200 day simple moving average is $12.66. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $21.55.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. NovoCure had a negative net margin of 20.79% and a negative return on equity of 38.82%. The company had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. During the same period last year, the business posted ($0.61) earnings per share. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that NovoCure will post -1.3 EPS for the current year.

Institutional Investors Weigh In On NovoCure

A number of hedge funds and other institutional investors have recently bought and sold shares of NVCR. Empowered Funds LLC bought a new stake in NovoCure in the 4th quarter valued at approximately $33,000. SJS Investment Consulting Inc. bought a new stake in shares of NovoCure in the third quarter worth $41,000. Kestra Advisory Services LLC bought a new stake in shares of NovoCure in the fourth quarter worth $49,000. Larson Financial Group LLC boosted its holdings in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in NovoCure in the second quarter valued at $88,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

More NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.